HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System.

Abstract
Depressive disorders represent protean psychiatric illnesses with heterogeneous clinical manifestations and a multitude of comorbidities leading to severe disability. In spite of decades of research on the pathophysiogenesis of these disorders, the wide variety of pharmacotherapies currently used to treat them is based on the modulation of monoamines, whose alteration has been considered the neurobiological foundation of depression, and consequently of its treatment. However, approximately one third to a half of patients respond partially or become refractory to monoamine-based therapies, thereby jeopardizing the therapeutic effectiveness in the real world of clinical practice. Recent scientific evidence has been pointing out the essential role of other biological systems beyond monoamines in the pathophysiology of depressive disorders, in particular, the glutamatergic neurotransmission. In the present review, we will discuss the most advanced knowledge on the involvement of glutamatergic system in the molecular mechanisms at the basis of depression pathophysiology, as well as the glutamate-based therapeutic strategies currently suggested to optimize depression treatment (e.g., ketamine). Finally, we will mention further "neurobiological targeted" approaches, based on glutamate system, with the purpose of promoting new avenues of investigation aiming at developing interventions that overstep the monoaminergic boundaries to improve depressive disorders therapy.
AuthorsCarmine Tomasetti, Chiara Montemitro, Annastasia L C Fiengo, Cristina Santone, Laura Orsolini, Alessandro Valchera, Alessandro Carano, Maurizio Pompili, Gianluca Serafini, Giampaolo Perna, Federica Vellante, Giovanni Martinotti, Massimo D Giannantonio, Yong-Ku Kim, Marco D Nicola, Antonello Bellomo, Antonio Ventriglio, Michele Fornaro, Domenico D Berardis
JournalCurrent pharmaceutical design (Curr Pharm Des) Vol. 25 Issue 4 Pg. 381-387 ( 2019) ISSN: 1873-4286 [Electronic] United Arab Emirates
PMID30864501 (Publication Type: Journal Article, Review)
CopyrightCopyright© Bentham Science Publishers; For any queries, please email at [email protected].
Chemical References
  • Excitatory Amino Acid Agents
  • Glutamic Acid
  • Ketamine
Topics
  • Depression (drug therapy)
  • Depressive Disorder, Major (drug therapy)
  • Excitatory Amino Acid Agents (therapeutic use)
  • Glutamic Acid
  • Humans
  • Ketamine
  • Synaptic Transmission

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: